[EN] TRIMETHYLANGELICIN AS CFTR CORRECTOR IN BRONCHIAL EPITHELIAL CELLS<br/>[FR] TRIMÉTHYLANGÉLICINE EN TANT QUE CORRECTEUR DE CFTR DANS LES CELLULES ÉPITHÉLIALES BRONCHIQUES
申请人:AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA DI VERONA
公开号:WO2012171954A1
公开(公告)日:2012-12-20
The invention relates to the use of 4,6,4 '-trimethylangelicin (TMA) and structural analogues thereof to prepare a medicament for the treatment of cystic fibrosis with the primary objective of correcting the defective CFTR in a sub-group of cystic fibrosis patients consisting of patients carrying the F508del-CFTR mutation.